<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7485949\results\search\disease\results.xml">
  <result pre="(CP), plasma collected from individuals who have recovered from an" exact="infectious disease," post="has been used to confer therapeutic benefits in previous"/>
  <result pre="diseases, including the H1N1 influenza pandemic (2009) and now coronavirus" exact="disease" post="2019 (COVIDâ€�19).1 Over the last several decades, as technology"/>
  <result pre="of immunoglobulins with known titers of neutralizing antibodies against specific" exact="infectious" post="agents, such as rabies, hepatitis B, and cytomegalovirus. CP"/>
  <result pre="of neutralizing antibodies against specific infectious agents, such as rabies," exact="hepatitis" post="B, and cytomegalovirus. CP or Hâ€�IG treatments have demonstrated"/>
  <result pre="have demonstrated clinical benefits in previous coronavirus epidemics. In severe" exact="acute" post="respiratory syndrome (SARS), caused by SARSâ€�coronavirus (CoV), highly homologous"/>
  <result pre="demonstrated clinical benefits in previous coronavirus epidemics. In severe acute" exact="respiratory" post="syndrome (SARS), caused by SARSâ€�coronavirus (CoV), highly homologous to"/>
  <result pre="clinical benefits in previous coronavirus epidemics. In severe acute respiratory" exact="syndrome" post="(SARS), caused by SARSâ€�coronavirus (CoV), highly homologous to SARSâ€�CoVâ€�2,"/>
  <result pre="influenza, passive immunotherapy lowers mortality, especially if administered early in" exact="disease" post="(within 5Â days of symptoms). Yet, these studies often"/>
  <result pre="in full force to consider approaches to treat and prevent" exact="infection" post="with SARSâ€�CoVâ€�2. Vaccines, which if effective will result in"/>
  <result pre="high purity polyclonal IgG and its subclasses in Hâ€�IG. In" exact="viral" post="diseases, antibodies exert effect by viral neutralization (blocking viral"/>
  <result pre="subclasses in Hâ€�IG. In viral diseases, antibodies exert effect by" exact="viral" post="neutralization (blocking viral cell entry and, therefore, replication), complement"/>
  <result pre="In viral diseases, antibodies exert effect by viral neutralization (blocking" exact="viral" post="cell entry and, therefore, replication), complement activation, opsonization, and"/>
  <result pre="therefore, replication), complement activation, opsonization, and antibodyâ€�dependent cellular cytotoxicity mediation." exact="Viral" post="neutralization is antigenâ€�specific; other antiviral activities are antigenâ€�nonspecific and"/>
  <result pre="the Spike protein, which is responsible for SARSâ€�CoVâ€�2 attachment to" exact="epithelial" post="cells, including pneumocytes. The antibodies in COVIDâ€�19 passive immunotherapies"/>
  <result pre="nonbinding recommendations for CP donation: donors must have had documented" exact="infection" post="with SARSâ€�CoVâ€�2 (realâ€�time polymerase chain reaction or serology) and"/>
  <result pre="(PK) characteristics for a commercially available IG (i.v.) product.6 The" exact="short" post="time of maximum plasma concentration (Tmax) and long T1â€�2"/>
  <result pre="infusion of Hâ€�IG may be sufficient for treatment in the" exact="acute" post="disease settings. In upcoming studies, it is important to"/>
  <result pre="of Hâ€�IG may be sufficient for treatment in the acute" exact="disease" post="settings. In upcoming studies, it is important to confirm"/>
  <result pre="PK of SARSâ€�CoVâ€�2 specific antibodies administered therapeutically in an active" exact="disease" post="state is similar the PK of IG (i.v.). Table"/>
  <result pre="experience to date with CP as therapy suggests that a" exact="lower" post="dose may be effective: this will be tested in"/>
  <result pre="diseases, including COVIDâ€�19, endogenous antibody production is nondetectable early in" exact="disease" post="(7 Thus, patients who have rapidly progressing yet early"/>
  <result pre="disease (7 Thus, patients who have rapidly progressing yet early" exact="disease" post="may benefit from the antibody boost that would come"/>
  <result pre="To date, several hundred HCPs have died from COVIDâ€�19.8 High" exact="infection" post="rates in HCPs translate to direct and indirect harm:"/>
  <result pre="as the individual HCP is infected and suffers from the" exact="disease" post="and is a potential fomite for new infection, additional"/>
  <result pre="theoretical concern that Hâ€�IG against coronavirus, including SARSâ€�CoVâ€�2, may potentiate" exact="disease" post="via a mechanism called antibodyâ€�dependent enhancement (ADE), and earlier"/>
  <result pre="and earlier studies of Hâ€�IG in SARS and Middle East" exact="respiratory" post="syndrome (MERS) have not provided enough information to extrapolate"/>
  <result pre="earlier studies of Hâ€�IG in SARS and Middle East respiratory" exact="syndrome" post="(MERS) have not provided enough information to extrapolate to"/>
  <result pre="ADE describes two basic phenomena mediated by virusâ€�specific antibodies: enhanced" exact="viral infection" post="and enhanced immunologic response in the advanced disease, independent"/>
  <result pre="describes two basic phenomena mediated by virusâ€�specific antibodies: enhanced viral" exact="infection" post="and enhanced immunologic response in the advanced disease, independent"/>
  <result pre="and enhanced immunologic response in the advanced disease, independent from" exact="viral" post="load. There are no data to date to suggest"/>
  <result pre="immature. The strongest set of data on ADE in coronavirus" exact="infections" post="come from SARSâ€�CoV. In vitro data suggest that although"/>
  <result pre="In vitro data suggest that although antiâ€�Spike protein serum inhibits" exact="viral" post="entry into epithelial cells incubating in SARSâ€�CoV inoculated medium,"/>
  <result pre="suggest that although antiâ€�Spike protein serum inhibits viral entry into" exact="epithelial" post="cells incubating in SARSâ€�CoV inoculated medium, there is enhanced"/>
  <result pre="to note that in SARS ~Â 80% of patients developed" exact="acute" post="respiratory distress syndrome (ARDS), coincidentally with IgG seroconversion. Preclinical"/>
  <result pre="note that in SARS ~Â 80% of patients developed acute" exact="respiratory" post="distress syndrome (ARDS), coincidentally with IgG seroconversion. Preclinical and"/>
  <result pre="in SARS ~Â 80% of patients developed acute respiratory distress" exact="syndrome" post="(ARDS), coincidentally with IgG seroconversion. Preclinical and clinical correlation"/>
  <result pre="COVIDâ€�19. J. Clin. Invest (2020). 10.1172/JCI138745 2Lai, S.T.Treatment of severe" exact="acute" post="respiratory syndrome. Eur. J. Clin. Microbiol. Dis.24, 583â€&quot;591 (2005)."/>
  <result pre="J. Clin. Invest (2020). 10.1172/JCI138745 2Lai, S.T.Treatment of severe acute" exact="respiratory" post="syndrome. Eur. J. Clin. Microbiol. Dis.24, 583â€&quot;591 (2005). 3Mairâ€�Jenkin,"/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systemic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systemic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systemic review and exploratory metaâ€�analysis."/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systemic review and exploratory metaâ€�analysis. J. Infect."/>
  <result pre="treatment of severe acute respiratory infections of viral etiology: a" exact="systemic" post="review and exploratory metaâ€�analysis. J. Infect. Dis.211, 80â€&quot;90 (2015).25030060"/>
  <result pre="of a novel human intravenous immunoglobulin 10% in patients with" exact="primary" post="immunodeficiency diseases: analysis of a phase III, multicenter, prospective,"/>
  <result pre="a novel human intravenous immunoglobulin 10% in patients with primary" exact="immunodeficiency" post="diseases: analysis of a phase III, multicenter, prospective, openâ€�label"/>
  <result pre="Covidâ€�19. &amp;lt;https://www.medscape.com/viewarticle/927976&amp;gt; (2020). Accessed April 30, 2020. 9Jaume, M.et al.Antiâ€�severe" exact="acute" post="respiratory syndrome coronavirus spike antibodies trigger infection of human"/>
  <result pre="&amp;lt;https://www.medscape.com/viewarticle/927976&amp;gt; (2020). Accessed April 30, 2020. 9Jaume, M.et al.Antiâ€�severe acute" exact="respiratory" post="syndrome coronavirus spike antibodies trigger infection of human immune"/>
  <result pre="(2020). Accessed April 30, 2020. 9Jaume, M.et al.Antiâ€�severe acute respiratory" exact="syndrome" post="coronavirus spike antibodies trigger infection of human immune cells"/>
  <result pre="9Jaume, M.et al.Antiâ€�severe acute respiratory syndrome coronavirus spike antibodies trigger" exact="infection" post="of human immune cells via a pHâ€� and cysteine"/>
  <result pre="J. Virol.85, 10582â€&quot;10597 (2011).21775467 10Liu, L.et al.Antiâ€�spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARSâ€�CoV"/>
  <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARSâ€�CoV infection. JCI Insight4, pii: 123158 (2019)."/>
 </snippets>
</snippetsTree>
